Skip to main content
Caplight Logo









Invaio Sciences

Invaio Sciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.invaio.com/

Last Round

Debt

Oct 13, 2021

Total Funding Raised

$192M

Company Overview

Invaio Sciences is an agricultural technology company that develops nature-positive crop health solutions by leveraging advanced biological platforms and precision delivery technologies to reduce pesticide use and improve crop yields.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Sustainable Materials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

agtechcrop protectionbiologicalspeptide-based biologicalstargeted deliverysustainable agriculturecitrus greeningbiotechai discovery engineintegrated pest managementin silico discoverynature-positiveprecision agricultureagribusinessbio-pesticides

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invaio Sciences Comparables

Compare Invaio Sciences with similar companies based on industry and business-model similarity.

Invaio Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Vive Crop Protection
81%
Vestaron
79%
AgroSpheres
79%

Invaio Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtOct 13, 2021
Series CMay 25, 2021
Series BFeb 5, 2020

Key People

Founding team and executive leadership

Scott D. Kantor

Chief Financial Officer

Executive Team

Invaio Sciences Investors

Notable investors and investment history

Invaio Sciences investors
InvestorRounds
Bluwave CapitalSeries C
Alexandria Venture InvestmentsSeries C
Stage 1 VenturesSeries C
Flagship PioneeringSeries C, Seed, Series B
K2 HealthVenturesDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 18, 2026

    Partnered with Ginkgo Bioworks to develop new manufacturing tech.

  • May 7, 2025

    Magalie Guilhabert, Ph.D. appointed as the new CSO.

Invaio Sciences Filings

Explore SEC and related filing metadata, where available.

Invaio Sciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Invaio Sciences's valuation, stock price, and market status.

Is Invaio a public or private company?

Invaio is a private company.

What is the current stock price of Invaio?

Invaio is a private company with no public stock price. No recent secondary market data is available.

How much is Invaio worth (valuation)?

Valuation information for Invaio is not publicly available.

Can I buy Invaio stock?

Invaio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Invaio's last funding round?

Invaio's most recent funding round was Debt on October 13, 2021.

Who are the main investors in Invaio?

Key investors in Invaio include Flagship Pioneering, K2 HealthVentures.

Will Invaio IPO soon?

No public IPO plans have been announced for Invaio.

How can I track Invaio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Invaio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range65
Year Founded2018
Last FundingOct 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?